REMARKS

Following entry of the foregoing amendments, claims 11-16 will be pending. Claim 13 has been amended. Support for the amended claim may be found throughout the specification including in the original claims, for example at page 57, lines 20-21, and in the sequence listing. No new matter is added by these amendments.

Rejections Under 35 U.S.C. § 101

The Examiner rejected claims 11-16 under 35 U.S.C. § 101, because the claimed invention allegedly "is not supported by either a specific asserted utility or a well established utility." Office Action at pages 2-3. The Board of Appeals and Interferences sustained the rejection on the basis that "the Specification...never connects ... [SEQ ID NO:48411] to any particular or specific utility." See Decision on Appeal 2008-2230 September 24, 2008, at pages 5-6.

Applicants respectfully request reconsideration in light of the additional evidence and arguments provided.

The specification as filed discloses that SEQ ID NO: 48411 has significant homology to the sequence disclosed in NCBI record CAA18117, which is associated with the sequence identifier "3046693" (i.e., gi:3046693). A review of that record indicates that the source of the sequence (DBSOURCE) is "embl accession AL022140.1". An examination of the record AL022140 indicates that the sequence associated with the identifiers CAA18117 and gi:3046693 has "strong similarity to ES43 protein..." of Barley (H. vulgare). Applicants respectfully submit that a skilled artisan would understand that barley ES43 protein is recognized in the art as a barley steroid hormone receptor. See, e.g., NCBI record X77575 and Speulman and Salamini, A barley cDNA clone with homology to the DNA-binding domain of the steroid receptor, Plant Sci. 106, 91-98 (1995).

¹ A copy of the record associated with CAA18117 gi:3046693 is provided for the Examiner's consideration.

² A copy of both record X77575 and Plant Sci. 106, 91-98 (1995) are provided for the Examiner's consideration.

In *In re Fisher*, the Federal Circuit reiterated that the "basic *quid pro quo* contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived from the public from an invention with *substantial utility*." *In re Fisher*, 421 F.3d 1365, 1371 (Fed. Cir. 2005) (citing *Brenner v. Manson*, 383 U.S. at 534-35, 1966) (emphasis in original). The Court noted that since "*Brenner* our predecessor court, the Court of Customs and Patent Appeals, and this court have required a claimed invention to have a specific and substantial utility to satisfy § 101." *Id.* Furthermore, an invention need only provide one identifiable benefit to satisfy 35 U.S.C. § 101. *See Raytheon Co. v. Roper Corp.*, 724 F.2d 951, 958 (Fed. Cir. 1983) ("when a properly claimed invention meets at least one stated objective, utility under section 101 is clearly shown").

Although the Supreme Court has not defined the meaning of the terms "specific" and "substantial", the Federal Circuit has identified a framework for the kind of disclosure an application could contain to establish a specific and substantial utility. *In re Fisher*, 421 F.3d at 1371. First, the Court indicated that, to provide a substantial utility, the specification should disclose a utility such that "one skilled in the art can use a claimed discovery in a manner which provides some *immediate benefit to the public*." *Id.* (emphasis in original). Second, a specific utility can be disclosed by discussing "a use which is not so vague as to be meaningless," that is that the claimed invention "can be used to provide a well-defined and particular benefit to the public." *Id.*

In view of the foregoing, a skilled artisan, at the time of the invention, would recognize that the nucleotide sequence of SEQ ID NO: 48411 can be employed to, among other things, be used to identify putative plant receptors, which influence a variety of processes through regulation of transcription. In other words, SEQ ID NO: 48411 has at least one utility specific to it and not generally applicable to any nucleic acid. Therefore, Applicants have disclosed at least one specific, substantial, and credible utility for the claimed invention that provides an immediate benefit to the public, and therefore the claimed invention meets the utility test set forth in *In re Fisher*. Thus, Applicants respectfully request that the Examiner withdraw the rejection of claims 11-16 under 35 U.S.C. § 101.

Rejections Under 35 U.S.C. § 112 first paragraph

A. The Claimed Invention is Supported by a Statutory Utility

The Examiner rejected claims 11-16 under 35 U.S.C. § 112, first paragraph, because, allegedly, "the claimed invention is not supported by either a specific asserted utility or a well established utility... one skilled in the art clearly would not know how to use the claimed invention." Office Action at pages 3-4. Applicants respectfully disagree with the rejection, and submit that this rejection has been overcome by the arguments set forth above with respect to the rejection under 35 U.S.C. § 101. In other words, Applicants respectfully submit that, since the claimed invention has at least one specific, substantial, and credible utility, the rejection of claims 11-16 with respect to the enablement requirement of 35 U.S.C. § 112, first paragraph must be withdrawn.

B. The Claimed Invention is Supported by an Adequate Written Description.

Applicants respectfully note the Decision of the Board of Appeals and Interferences reversing the rejection of clams 11-15 under 35 U.S.C. § 112 for allegedly lacking an adequate written description. *See Decision on Appeal* 2008-2230 September 24, 2008, at pages 6-7.

Rejections Under 35 U.S.C. § 102

The Examiner rejects claim 13 under 35 U.S.C. § 102(b) over Maharias *et al.* (Gen EMBL Accession No. AQ451805). The Board of Appeals and Interferences affirmed the decision on the basis that the 21 nucleotide fragment present in Maharias reads on "about 30" nucleotides.

Applicants respectfully disagree. In order to advance prosecution, however, Applicants have amended claim 13 to delete the term "about." In view of the foregoing, Applicants respectfully request reconsideration and withdrawal of the rejection.

CONCLUSION

In view of the above, each of the presently pending claims is believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to pass this application to issue. The Examiner is encouraged to contact the undersigned at (202) 942-5000 should any additional information be necessary for allowance.

Respectfully submitted,

Joseph W. Ricigliano (Reg. No. 48, 511)

Holly Logue Prutz (Reg. No. 47,755)


repla heighing

David R. Marsh (Reg. No. 41,408)

Date: November 19, 2008

ARNOLD & PORTER LLP

Attn: IP Docketing 555 12th Street, N.W. Washington, D.C. 20004 (202) 942-5000 telephone (202) 942-5999 facsimile



```
/db_xref="GOA:065462"

/db_xref="HSSP:Q80TJ7"

/db_xref="InterPro:IPR001025"

/db_xref="InterPro:IPR001965"

/db_xref="InterPro:IPR011011"

/db_xref="InterPro:IPR013032"

/db_xref="UniProtKB/TrEMBL:065462"

ORIGIN

1 gdcvlmrpsd agkppyvarv ekieadarnn vkvhcrwyyr peeslggrrq fhgakelfls
61 dhfdvqsaht iegkcivhtf knytrlenvg aedyycrfey kaatgaftpd rvavyckcem
121 pynpddlmvq cegckdwyhp acvgmtieea kkldhfvcae cssdddvkks qngftsspad
181 dvkvrlslfs hllyrcsity l
```

<u>Disclaimer | Write to the Help Desk</u> <u>NCBI | NLM | NIH</u>

Last update: Wed, 24 Sep 2008 Rev. 141210



```
241 tggccaagat tgaggaaatc gaggcagcag gacctcgggg cgcaaatgtc aaggttaaag 301 tgcggtggta ctaccggca gaagagtcta ttggtgggcg gaggccattc cattgcgaaa 361 aggaggtgtt cctctccgac caccaagatg tgcagagtgc tgacaccata gagtgcaagt 421 gcaatgtcta cagettccgg gactacacca agettgctgc tgtcaatcct gaggactatt 481 tttgccgctt cgagtaccag tcaatcacag gcagetttgt gcctgaccgc atagetgtgt 541 tttgcaagtg tgagatgcca tacaaccctg acgatcttat gatccagtgt gaggaatgct 601 ctgattggtt tcaccctgct tgtattggaa agaccataaa agaagcaaag aagettgaga 661 attttacatg cgaaggttgc gttgctgaaa atggaaatgc gaatggagc 781 ggtgaaggcg aaggcgatct ggacggaagt cctccatct ttcatgcatg tgatggggg 841 gatgtacatt gctgttcca gtttgatgta gaacgaacct gtattggga cctgtctgg 901 agtctgagt tggcagtcgg ccagtttgc gacgaacct gtattggga cctgtctgt 961 tagagggagt cattatttt ctctcttct ttttccttcg ccccccttt gtgtcgact 1021 ggactatggt gagtgagctt aaacgtcctt ccttgact
```

Disclaimer | Write to the Help Desk NCBI | NLM | NiH

Last update: Wed, 05 Nov 2008 Rev. 145015

PLANT SCIENCE

an international journal of experimental plant biology

CHIEF EDITOR:

J.H. WEIL, Strasbourg (France)

EDITORIAL BOARD

- J. Amesz, Leiden
- K. Apel, Zürich
- D. Bartels, Köln
- P. Benveniste, Strasbourg
- T. Boller, Basel
- A. Brennicke, Berlin
- R. Chollet, Lincoln, NE
- R.E. Cleland, Seattle, WA
- M. Delseny, Perpignan, France
- R. Douce, Grenoble
- D.K. Dougall, Knoxville, TN
- D. Dudits, Szeged
- G. Forti, Milan
- M. Furuya, Saitama
- P. Gadal, Orsay

- J. Gressel, Rehovot
- H. Han, Beijing
- R. Haselkorn, Chicago, IL
- R. Herrmann, Munich
- F. Hoffmann, Irvine, CA
- K. Kamo, Beltsville, MD
- E. Kombrink, Köln
- T. Kutchan, Munich
- P.J. Lea, Lancaster
- A.B. Legocki, Posnan
- J. Leemans, Gent
- H. Lörz, Hamburg
- P. Mazliak, Paris
- M. Monsigny, Orléans
- T.W. Okita, Pullman, WA

- B. Parthier, Halle (Saale)
- D.W. Rains, Davis, CA
- R. Ranjeva, Toulouse, France
- T. Reynolds, Charlotte, NC
- K. Richards, Strasbourg
- B. Rubinstein, Amherst, MA
- C.A. Ryan, Pullman, WA
- J.N. Siedow, Durham, NC
- H. Stafford, Portland, OR
- G.A. Strobel, Bozeman, MT
- M. Sugiura, Nagoya
- D. Tepfer, Versailles, France
- I.K. Vasil, Gainesville, FL
- D.P.S. Verma, Columbus, OH
- C.F.L. Woodcock, Amherst, MA

Volume 106 (1995)



ELSEVIER

Amsterdam - Lausanne - New York - Oxford - Shannon - Tokyo



Plant Science 106 (1995) 91-98



A barley cDNA clone with homology to the DNA-binding domain of the steroid hormone receptors *

Elly Speulman¹, Francesco Salamini*

Max-Planck-Institut für Züchtungsforschung, Carl-von-Linnéweg 10, 50829 Köln, Germany

Received 2 November 1994; revision received 12 January 1995; accepted 13 January 1995

Abstract

The steroid hormone receptors are members of a superfamily of nuclear receptors that regulate gene expression in response to a ligand in mammals and insects. A cDNA library from barley (*Hordeum vulgare*) was screened with highly degenerated oligonucleotides corresponding to 11 and 6 amino acids of the highly conserved DNA-binding domain of the steroid hormone receptors. A full length cDNA clone (ES43) was isolated. The sequence of ES43 shows homology to the DNA-binding domain of the estrogen receptor, including three amino acids (Glu¹⁹¹, Gly¹⁹² and Ala¹⁹⁵) at conserved positions, which determine the binding specificity of the estrogen receptor to its hormone response element. Additional homologies concerning critical amino acid positions with all members of the nuclear receptor superfamily are also evident.

Keywords: Hordeum vulgare; Steroid hormone receptors; DNA-binding domain; Zinc-finger

1. Introduction

Steroid hormones, plant sterols, and gibberellins are products of the terpenoid pathway with close structural relationships. The steroid hormones regulate events involved in development and dif-

All receptors cloned so far, share a similar structure: a variable N-terminal region, a highly conserved cysteine rich domain and an only partly conserved C-terminal region, where the ligand

ferentiation in mammals and insects. They mediate their effect through binding to specific high affinity receptors [1] which belong to a superfamily of nuclear receptors for the steroid and thyroid hormones, vitamin D_3 and retinoic acid. Gene expression in response to a ligand is modulated by the receptor through binding to specific hormone response elements (HREs) in the promoter of target genes [1,2]. To date, no homologs of this class of transcription factors have been reported isolated from plants.

The nucleotide sequence data reported in this paper will appear in the EMBL, GenBank and DDBJ Nucleotide Sequence Databases under the accession number X77575 H.vulgare (Dbg576) ES43 mRNA.

^{*} Corresponding author, Tel.: (+49-221) 5062400; Fax: (+49-221) 5062413.

¹ Department of Biological Sciences, Wye College, Wye, Ashford, Kent TN25 5AH, UK.

binding domain is located [3,4]. The highly conserved DNA-binding domain, corresponds to the cysteine rich region, with cysteine residues arranged into two zinc fingers, each of them with a zinc ion tetrahedrally coordinated by four cysteines [5]. The two zinc finger motifs have separate functions. The N-terminal finger serves as the primary DNA-recognition unit and three distinct amino acids are responsible for the specific binding of the receptors to their response element [6,7]. The steroid and thyroid receptors bind as dimers to their hormone response element. The C-terminal zinc finger motif is responsible for these protein interactions between two receptor molecules [8].

Steroid hormone receptors have been shown to function as hormone dependent inducers of gene expression in yeast and plants [9-11]. Expression of the genes encoding the human estrogen and glucocorticoid receptor in yeast and tobacco results in transactivation of a hybrid promoter carrying HRE sequences in a hormone specific dependent manner [9,10]. The molecular mechanisms underlying this activation must, therefore, be very well conserved across eukaryotes.

Gibberellins regulate several developmental and differentiation processes in plants. Like other plant hormones, they may act through tissue specific receptors. The structural relationship between steroid hormones, vitamin D, retinoic acid and gibberellins might imply a relationship between the receptors. This relationship suggested an approach to isolate steroid hormone receptor homologs from plants with the aim of isolating nuclear receptors, and potentially plant hormone receptors.

In this paper we describe the isolation of a barley cDNA clone that shares homology with the DNA-binding domain of the nuclear hormone receptors.

2. Material and methods

2.1. Plant material

A GA-sensitive barley dwarf mutant, Dornburg 576 (dbg576), kindly provided by Dr W. Hentrich, was grown in the greenhouse under 16 h light/8 h dark conditions at 18°C day/ 12°C night, with a light intensity of around 270 μ E·m⁻²·s⁻¹.

2.2. RNA isolation and analysis

Poly(A)⁺RNA was isolated from 2-month-old dbg576 leaves, as described in Bartels and Thompson [12]. Total RNA was isolated from 2-monthold dbg576 tissue, according to Koes et al. [13]. For Northern analysis, 2 µg of poly(A)+RNA or 10 µg of total RNA was separated on a 1.3% formaldehyde-agarose gel [14], and blotted onto a GeneScreen Plus membrane (NEN, duPont), according to the manufacturer's instructions. The filter was hybridized for 24 h at 58°C in 1 M NaCl, 10% dextran sulfate (Pharmacia), 1% SDS, 200 μg/ml denatured herring sperm DNA, and ³²Plabelled NotI-SalI ES43 digested insert. Labelling was according to Feinberg and Vogelstein [15]. The filter was washed for 2×5 min in $2 \times SSC$ at room temperature and for 2×30 min in $2 \times$ SSC, 1% SDS at 58°C.

2.3. Degenerated oligonucleotides

Degenerated oligonucleotides were purified over NAPTM-10 columns (Pharmacia). The oligonucleotide sequences were, for oligo A, ACI TG(C/T) GA(A/G) GGI TG(C/T) AA(A/G) GGI TT(T/C) TT(T/C) CGI (A/C)G, corresponding to the amino acids TCEGCKGFFKR, and for oligo B, AC(AGGC/T) TG(C/T) GA(A/G) GG(AGGC/T) TG (C/T) AAG, corresponding to the amino acids TCEGCK.

2.4. Construction and screening of a cDNA library

A cDNA library was constructed from 2 μg poly(A)+RNA of GA3-treated dwarf mutant leaves, using the Superscript[™] system (BRL, Life Technologies), and competent cells of the bacterial strain DH5\alpha (BRL, Life Technologies), according to the manufacturers instructions. Transformants were plated onto YT plates containing 100 μg/ml of ampicillin and, after overnight incubation at 37°C, transferred to Colony/Plaque Screen™ discs (NEN, duPONT). Around 70 000 colonies were hybridized with oligo A or B. The oligonucleotides were 5'-end labelled according to Sambrook et al. [14], using 5000 Ci/mmol [7-³²PlATP (Amersham). Filters were prehybridized in 1 M NaCI, 10% dextran sulfate, 1% SDS for at least 12 h at 47°C for oligo A and at 33°C for oligo B. Approximately 10⁶ counts/min (1 ng) of la-





Fig. 1. Nucleotide and predicted amino acid sequence of ES43. Nucleotide sequence of full length ES43 is presented in the 5' to 3' orientation with numbering at the left side of the sequence. The translational open reading frame is shown below the nucleotide sequence with numbering at the right side of the sequence. Cysteine residues are shown in bold. The potential zinc-finger is underlined. The position of the poly-A-tail is marked as (A)_x.



belled oligonucleotide per ml of hybridization solution were hybridized for 48 h at 47°C for oligo A and at 33°C for oligo B. Filters were washed for 3×5 min in $6 \times$ SSC, 0.05% sodium-pyrophosphate and for 15 min in $6 \times$ SSC, 0.05% sodium-pyrophosphate at, respectively 47°C and 33°C. Exposure of the filters to XAR films (KODAK) was for 48 h at -70°C.

2.5. DNA sequencing

The DNA sequences were determined by the chain termination method on double stranded templates [16] using the ^{T7}Sequencing kit (Pharmacia). The cDNA clones were sequenced with sequence specific oligonucleotides in forward and reverse mode. Sequence assembly and analysis were done with programs from the GCG software package 7.1 [17].

3. Results

3.1. Isolation and sequence of ES43

Around 70 000 colonies of a barley cDNA library were screened with the degenerated oligonucleotides A and B, which correspond to the most conserved region of the DNA-binding domain of the nuclear hormone receptors. The DNA-binding domain of the nuclear hormone receptors represents the most conserved region and was

therefore preferred to the relatively low conserved ligand binding domain, which was expected not to be evolutionary conserved. One cDNA clone was found positive with oligo A, but after sequence analysis revealed a potential zinc finger not related to the DNA binding domain of the steroid hormone receptors. Of two cDNA clones found positive with oligo B one, designated ES43, contained the oligonucleotide sequence used for screening and a potential zinc finger motif.

Sequence analysis of ES43 revealed an insert of 1058 bp (Fig. 1). The deduced amino acid sequence is 227 amino acids long, which would correspond to a molecular weight of 26 kDa. The protein is relatively rich in cysteines (11 residues). Six cysteines are positioned in the first part of the protein, and seem to be located at fixed positions in a repeat (Fig. 2A). Homologies between this part of ES43 and proteins in the databases were restricted to only small portions of the protein and concerned the conserved positions of cysteines in proteins containing cysteine rich regions. Five cysteine residues are located in the C-terminal region and encode a putative zinc-finger between amino acids 160 and 200 (Fig. 2B). The region covering oligonucleotide B (TCEGCK), responsible for specific DNA-binding of the estrogen receptor to its hormone response element (HRE), is located between amino acids 189 and 194. A po-

Fig. 2. Features of ES43 and the nuclear hormone receptors. (A) Sequence alignment of the 5' part of ES43, between amino acids 84 and 118 and between 127 and 161. Conserved cysteine residues are shown in bold. Homologous amino acids are indicated with an asterisk. (B) Potential zinc-finger of ES43 between amino acids 160 and 201. The amino acid residues Glu 191, Gly 192 and Ala 195, determine binding specificity of the estrogen receptor and are shown in bold-italic. (C) The DNA-binding domain of the estrogen receptor represented as two zinc-fingers. The amino acid residues Glu²⁵, Gly²⁶ and Ala²⁹ are shown in bold-italic. The position of the intron in the steroid hormone receptors (SH) and the retinoic acid receptors (RAR) and thyroid hormone receptors (TR) are indicated. (D) Alignment of ES43 with members of the nuclear hormone receptor family. Amino acid residues homologous to ES43 are shown in bold. Amino acids, homologous or conserved by hydrophobicity or charge, between ES43 and the receptors are boxed. For conservation comparisons, the following groups of residues have been used: P,A,G,S,T (neutral or weakly hydrophobic); O.N.E.D (hydrophilic, acid amine); H.K.R (hydrophilic, basic); L.I.V.M.F.Y.W (hydrophobic). Estrogen receptor (ER), Retinoic acid receptor (RAR), Vitamin D (Vit D), Thyroid hormone receptor (TR), Ecdysone receptor (EcR), Glucocorticoid receptor (GR). (E) Alignment of ES43 with the most closely related members of the nuclear receptor family. Amino acid residues homologous to ES43 are shown in bold. Amino acids, homologous or conserved by hydrophobicity or charge, between ES43 and the receptors are boxed. (F) Helical wheel representation of the potential α-helix in the zinc finger of ES43 (left) and the α-helix of the estrogen receptor (right). Amino acid residues are marked according to their position in Fig. 2B and C, respectively. Amino acids in the α-helix of ES43 with positional homology to the DNA-binding amino acid residues of the ER, are marked with identical symbols. Hydrophobic residues are boxed. (G) Alignment of ES43 with part of the most conserved region of the ligand-binding domain of the retinoic acid receptors. Homologous amino acid residues are shown in bold. Amino acid residues, homologous, or conserved by hydrophobicity or charge, between ES43 and the receptors are boxed.

tential secondary structure of the protein was derived using the algorithm of Garnier et al. [18]. The structure is alternated by β -strands, turns and α -helices. The 5' and 3' regions are highly hydrophilic, while the center is mainly hydrophobic.

3.2. Structure of the potential zinc finger motif in ES43

The potential zinc finger motif of ES43 is defined by four cysteine metal ligands, arranged as a Cys- X_2 -Cys- X_2 -Cys- X_2 -Cys- X_2 -Cys (C_2 - C_2) motif. This arrangement is homologous to both zinc finger motifs found in the steroid receptors (Fig. 2C). However, the loop of 23 amino acids between C_2 and C_2 in ES43 is longer than the 13 amino acids usually found in the loop of the steroid receptor zinc finger motifs. Loops of 20–30 amino acids are found in the putative zinc fingers of the mammalian poly(ADP)-ribose polymerase [19] and uvrA from E. coli [20].

Other zinc-finger configurations in ES43 are possible between amino acids Cys¹⁶⁶ and His¹⁷¹ and between Cys¹⁹⁰ and Cys¹⁹³ resulting in a Cys-X₄-His-X₁₇-Cys-X₂-Cys arrangement or between His¹⁷¹ and Cys¹⁷³ and between Cys¹⁹⁰ and Cys¹⁹³ giving a His-X₂-Cys-X₁₄-Cys-X₂-Cys arrangement. Neither of these arrangements has yet been reported, although Cys-X₂-Cys-X_n-His-X_n-Cys type fingers exist [21].

3.3. Homology of ES43 with steroid hormone receptors

ES43 shows homology with the DNA-binding domain of all members of the nuclear hormone receptor family (Fig. 2D). Amino acids homologous or conserved with respect to hydrophobicity and charge, between ES43 and the receptors are boxed in Fig. 2D and E. Three amino acids, Glu²⁵, Gly²⁶ and Ala²⁹ (see Fig. 2C for numbering) determine the specific binding of the estrogen receptor to its DNA response element [6,7]. These three amino acids are present in ES43 at positions Glu¹⁹¹, Gly¹⁹² and Ala¹⁹⁵ and are positioned in the zinc finger motif equal to the estrogen receptor.

Homologies with several receptors also concern the amino acids Asp¹⁶⁸ and Gly¹⁷⁶ positioned in the N-terminal part of the zinc finger, and other residues in the C-terminal part of the finger. In addition, a region of basic amino acids present in the loop of the C-terminal Zn-finger of all receptors, and involved in non-specific DNA-binding, is also present in ES43 (K²²³-R²²⁷). This short stretch of very basic amino acids might also be functional as a nuclear localization signal (NLS) of the ES43 protein [22]. Homologies are also evident with the genes egon, knirps and seven-up which belong to the nuclear hormone receptor superfamily, but are as yet without known ligand (Fig. 2E) [23]. The homologies extend to amino acids independent from the oligonucleotide used for screening and relate to amino acids M¹⁶⁰, Q¹⁶² and F¹⁸⁸.

3.4. Discrepancies between ES43 and steroid hormone receptors

A discrepancy is the addition of 10 amino acids in the loop of the zinc finger. These additional amino acids are part of a potential α -helix between amino acid residues 178 and 193, according to the algorithm of Garnier et al. [18] (Fig. 2F, left), and shows strong homology to the α -helix of the estrogen receptor (Fig. 2F, right). The amino acids, E²⁵, G²⁶, K²⁸, K³² and Q³⁶, responsible for specific binding to the ERE, correspond exactly in their mutual spacing with, respectively, E¹⁹¹, G¹⁹², N¹⁸⁷, K¹⁸⁴ and K¹⁸⁰ of ES43. Interestingly, this additional region shows a strong homology with part of the most conserved region of the ligand binding domain of the retinoic acid receptors (Fig. 2G) which is, however, always located Cterminally to the DNA-binding domain [4]. The DNA recognition helices of the estrogen and glucocorticoid receptors are located in a 3' position with respect to the first zinc-finger between amino acids 24 and 36 [6,24]. ES43 has no clear α -helix at this position. The position of the α -helix in ES43 shows homology to the position of the helix found in C2-H2 zinc-fingers, where the two histidines are located in the recognition helix, which is further extended into the loop [25,26].

ES43 contains only one putative zinc finger, whereas in the steroid hormone receptor family two zinc fingers are present. In the steroid hormone receptors, the first zinc finger is responsible for specific DNA-binding and the second for protein-protein (dimer) interactions. Amino acid residues responsible for dimerization are present in




Fig. 3. Expression of ES43 in different tissues. (A) Northern blot containing 2 μ g of poly(A)+RNA from leaf blades (lb). (B) Northern blot containing 10 μ g total RNA from leaf sheaths, leaf blades and young apices (ap) of the barley dwarf mutant. Filters were probed with labelled ES43 insert. (C) Fragment (panel shows 18-S RNA) of the gel used in (B) stained with methylene blue-as a control for loading.

the so-called D-loop, between Cys⁴³ and Cys⁴⁹ (Fig. 2C). Similarities between ES43 and the D-loop of the ER are present (Fig. 2D).

3.5. Southern and Northern analyses

Southern blot analysis showed that the sequence of ES43 is represented by not less than four copies in the barley genome (data not shown). The retinoic acid receptors are encoded by at least three genes. The thyroid hormone receptors by at least two. The steroid hormone receptors are encoded by single copy genes [2].

Northern blot analysis of poly(A)⁺RNA from leaf blades showed the expression of low-abundant transcripts varying in size between 800 and 1100 nucleotides (Fig. 3a). Several distinct transcripts varying in size between 750 and 1250 nucleotides were also detected in total RNA of leaf sheaths, leaf blades and young apices (Fig. 3b).

For the retinoic acid, estrogen, ecdysone and vitamin D receptors, more than one transcript is expressed by the same gene [2,27]. These isoforms are assembled by alternative promoter usage, and for the retinoic acid- and thyroid hormone receptors, also by differential splicing.

4. Discussion

The cDNA clone described, contains a domain very homologous to the DNA-binding domain of the nuclear hormone receptor family. Homologies were found with all members of this family, and were not limited to the sequence of the oligonucleotide used for screening. This is, to our knowledge, the first report on homologies between plant genes and the nuclear hormone receptor family. In addition, no plant homologs of ES43 were found in the *Arabidopsis* and protein databases.

The ES43 protein contains one putative zinc finger, in contrast to the steroid receptors, which always contain two zinc fingers. In the steroid hormone receptors, the two zinc fingers have different functions. The N-terminal finger is involved in specific DNA-binding and contains sufficient information to determine target specificity among the hormone response elements in vivo [28]. The strong homology between the recognition helix of the steroid receptors, and the α -helix of ES43 and particularly the identities in the mutual spacing between the DNA-binding amino acids of the ER and corresponding amino acids in ES43, suggests that ES43 should be sterically capable to bind to an ERE or a derivative.

Homologies with the ligand binding domain of the steroid hormone receptors were, besides of a short sequence in the zinc-finger motif of ES43, not evident. Considering its low conservation among all nuclear receptors, the ligand binding domain was not expected to be present in ES43 in its usual structure.

The ES43 protein contains a repeat of cysteine residues. Cysteine rich repeats that function as ligand binding domains are found in several receptor proteins not related to the steroid hormone receptors, i.e. the LDL (low density lipoprotein) receptor [29], the EGF receptor [30], the insulin receptor [31] and other members of the tyrosine protein kinase family. The cysteine repeat of ES43 could therefore be considered as a putative target for ligand binding studies.

References

- K.R. Yamamoto, Steroid receptor regulated transcription of specific genes and networks. Annu. Rev. Genet., 19 (1985) 209-252.
- [2] H. Gronemeyer, Transciption activation by estrogen and progesterone receptors. Annu. Rev. Genet., 25 (1991) 89-123.
- [3] S. Green and P. Chambon, Nuclear receptors enhance

- our understanding of transcription regulation. Trends Genet., 4 (1988) 309-314.
- [4] M.R. Koelle, W.S. Talbot, W.A. Segraves, M.T. Bender, P. Cherbas and D.S. Hogness, The *Drosophila EcR* gene encodes an ecdysone receptor, a new member of the steroid receptor superfamily. Cell, 67 (1991) 59-77.
- [5] L.P. Freedman, B.F. Luisi, Z.R. Korszun, R. Basavappa, P.B. Sigler and K.R. Yamamoto, The function and structure of the metal coordination sites within the glucocorticoid receptor DNA binding domain. Nature, 334 (1988) 543-546.
- [6] B. Luisi, W.X. Xu, Z. Otwinowski, L.P. Freedman, K.R. Yamamoto and B. Sigler, Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature, 352 (1991) 497-505.
- [7] S.M. Mader, V. Kumar, H. de Verneuil and P. Chambon, Three amino acids of the oestrogen receptor are essential to its ability to distinguish an oestrogen from a glucocorticoid-responsive element. Nature, 338 (1989) 271-274.
- [8] T. Härd, E. Kellenbach, R. Boelens, B.A. Maler, K. Dahlman, L.P. Freedman, J. Carlstedt-Duke, K.R. Yamamoto, J.-A. Gustafsson and R. Kaptein, Solution structure of the glucocorticoid receptor DNA-binding domain. Science, 249 (1990) 157-160.
- [9] D. Metzger, J.H. White and P. Chambon, The human oestrogen receptor functions in yeast. Nature, 334 (1988) 31-36.
- [10] M. Schena, A.M. Lloyd and R.W. Davis, A steroid inducible gene expression system for plant cells. Proc. Natl. Acad. Sci. USA, 88 (1991) 10421-10425.
- [11] A.M. Lloyd, M. Schena, V. Walbot and R.W. Davis, Epidermal cell fate determination in *Arabidopsis*: patterns defined by a steroid-inducible regulator. Science, 266 (1994) 436-439.
- [12] D. Bartels and R.D. Thompson, The characterization of eDNA clones coding for wheat storage proteins. Nucl. Acids Res., 11 (1983) 2961-2978.
- [13] R.E. Koes, C.E. Spelt and J.N.M. Mol, The chalcone synthase multigene family of *Petunia hybrida* (V30): differential, light regulated expression during flower development and UV light induction. Plant Mol. Biol., 12 (1989) 213-225.
- [14] J. Sambrook, E.F. Fritsch and T. Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989.
- [15] A.P. Feinberg and B. Vogelstein, A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem., 137 (1984) 266-267.
- [16] F. Sanger, S. Nicklen and A.R. Coulson, DNA sequenc-

- ing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA, 74 (1977) 5463-5467.
- [17] J. Devereux, P. Haeberli and O. Smithies, A comprehensive set of sequence analysis programs for the Vax. Nucl. Acids Res., 12 (1984) 387-395.
- [18] J. Garnier, D.J. Osguthorpe and B. Robson, Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins. A simple model. J. Mol. Biol., 120 (1978) 97-120.
- [19] K. Uchida, T. Morita, T. Sato, T. Ogura, R. Yamashita, S. Noguchi, H. Suzuki, H. Nyunoya, M. Miwa and T. Sugimura, Nucleotide sequence of a full length cDNA for human fibroblast poly(ADP-ribose) polymerase. Biochem. Biophys. Res. Commun., 148 (1987) 617-622.
- [20] R.F. Doolittle, M.S. Johnson, I. Husain, B. van Houten, D.C. Thomas and A. Sancar, Domainal evolution of a prokaryotic DNA repair protein and its relationship to active-transport proteins. Nature, 323 (1986) 451.
- [21] J.M. Berg, Zinc fingers and other metal-binding domains. J. Biol. Chem., 265 (1990) 6513-6516.
- [22] J. Garcia-Bustos, J. Heitman and M.N. Hall, Nuclear protein localization. Biochim. Biophys. Acta, 1071 (1991) 83-101.
- [23] M. Rothe, U. Nauber and H. Jäckle, Three hormone receptor-like Drosophila genes encode an identical DNA-binding finger. EMBO J., 8 (1989) 3087-3094.
- [24] J.W.R. Schwabe, D. Neuhaus and D. Rhodes, Solution structure of the DNA-binding domain of the oestrogen receptor. Nature, 348 (1990) 458-461.
- [25] R.M. Evans and S.M. Hollenberg, Zinc fingers: gilt by association. Cell, 52 (1988) 1-3.
- [26] D. Rhodes and A. Klug, Zinc fingers. Sci. Am., (1993) 32-39
- [27] F.D. Karim and C.S. Thummel, Temporal coordination of regulatory gene expression by the steroid hormone ecdysone. EMBO J., 11 (1992) 4083-4093.
- [28] T.K. Archer, G.L. Hager and J.G. Omichinski, Sequence specific DNA binding by glucocorticoid receptor zinc finger peptides. Proc. Natl. Acad. Sci. USA, 87 (1990) 7560-7564.
- [29] D.W. Russell, W.J. Schneider, K.L. Yamamoto, M.S. Lusky, M.S. Brown and J.L. Goldstein, Domain map of the LDL receptor: sequence homology with the epidermal growth factor precursor. Cell, 37 (1984) 577-585.
- [30] S. Pfeffer and A. Ullrich, Epidermal growth factor: is the precursor a receptor? Nature, 313 (1985) 184.
- [31] K.L. Thompson, S.J. Decker and M.R. Rosner, Identification of a novel receptor in *Drosophila* for both epidermal growth factor and insulin. Proc. Natl. Acad. Sci., 82 (1985) 8443-8447.